We're excited to announce the appointment of Adam Hughes, Ph.D., as Chief Scientific Officer at Vicinitas! Adam's extensive experience discovering heterobifunctional molecules and advancing platform-derived clinical candidates, coupled with his demonstrated leadership skills, will be critical as we continue to build a discovery pipeline of differentiated therapeutics for cancer and genetic disorders leveraging our proprietary targeted protein stabilization platform. Read press release: https://bit.ly/4bb6V1o
关于我们
Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell. In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation. To date, many aberrantly degraded proteins have been considered “undruggable” or intractable to drug discovery efforts. Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquitinase Targeting Chimeras (DUBTACs). The company’s mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. Spun out of an academic-industry collaboration between Novartis Institutes for BioMedical Research and the University of California, Berkeley, Vicinitas Therapeutics is based in South San Francisco, California.
- 网站
-
https://www.vicinitastx.com
Vicinitas Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- South San Francisco，California
- 类型
- 私人持股
地点
-
主要
获取路线
US，California，South San Francisco